PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals today announced positive results from a Phase 1 clinical trial of AN2898, an investigational topical anti-inflammatory product candidate for the potential treatment of psoriasis and atopic dermatitis. In the trial, AN2898 ointment was very well tolerated and demonstrated no irritant potential.
